-
Feb 09, 2021 10:00 AM IST -
Jan 18, 2021 11:15 PM IST Net Sales are expected to increase by 10.4 percent Y-o-Y (up 7.6 percent Q-o-Q) to Rs. 2,315.2 crore, according to Prabhudas Lilladher.
-
Nov 26, 2020 05:51 PM IST New Delhi, Nov 26 Drug firm Jubilant Life Sciences on Thursday said it has issued commercial papers worth Rs 90 crore. Tenure of the instrument i..
-
Nov 12, 2020 04:02 PM IST Prabhudas Lilladher recommended accumulate rating on Jubilant Life Sciences with a target price of Rs 752 in its research report dated November 05, 2020.
-
Nov 10, 2020 12:07 PM IST Motilal Oswal is bullish on Jubilant Life Sciences recommended buy rating on the stock with a target price of Rs 855 in its research report dated November 04, 2020.
-
Nov 09, 2020 11:54 AM IST ICICI Direct is bullish on Jubilant Life Sciences recommended buy rating on the stock with a target price of Rs 850 in its research report dated November 08, 2020.
-
Nov 06, 2020 09:11 AM IST -
Nov 05, 2020 05:34 PM IST The company had posted a net profit of Rs 249.39 crore for the corresponding period of the previous fiscal, Jubilant Life Sciences said in a BSE filing.
-
Nov 05, 2020 04:22 PM IST -
Sep 07, 2020 07:14 PM IST Motilal Oswal is bullish on Jubilant Life Sciences recommended buy rating on the stock with a target price of Rs 975 in its research report dated September 05, 2020.
-
Sep 07, 2020 06:51 PM IST Prabhudas Lilladher is bearish on Jubilant Life Sciences has recommended sell rating on the stock with a target price of Rs 446 in its research report dated September 07, 2020.
-
Sep 07, 2020 06:48 PM IST ICICI Securities recommended hold rating on Jubilant Life Sciences with a target price of Rs 822 in its research report dated September 05, 2020.
-
Sep 07, 2020 11:06 AM IST Consolidated total revenue from the operations of the company stood at Rs 1,892.92 crore for the quarter under consideration. It was Rs 2,181.86 crore for the same period a year ago, the company said.
-
Aug 08, 2020 07:35 PM IST The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the company's distribution network, Jubilant Life Sciences said in a statement.
-
Jul 21, 2020 12:00 PM IST The company's subsidiary Jubilant Generics has received the approval from Drug Controller General of India (DCGI) to manufacture and market investigational drug Remdesivir 100 mg/vial (lyophilized injection).
-
Jun 16, 2020 12:44 PM IST Rakesh Radheshyam Jhunjhunwala held 4.41 percent stake (or 70.25 lakh equity shares) in the pharma company as per March shareholding pattern available on exchanges.
-
Jun 14, 2020 03:51 PM IST Anand Rathi is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 867 in its research report dated June 12, 2020.
-
Jun 02, 2020 11:30 AM IST Prabhudas Lilladher recommended Hold rating on Jubilant Life Sciences with a target price of Rs 414 in its research report dated Jun 01, 2020.
-
Jun 02, 2020 09:31 AM IST -
Jun 02, 2020 09:31 AM IST -
Jun 02, 2020 08:46 AM IST ICICI Direct is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 550 in its research report dated Jun 01, 2020.
-
Jun 01, 2020 03:21 PM IST Motilal Oswal is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 515 in its research report dated May 30, 2020.
-
May 29, 2020 08:39 PM IST Consolidated revenue from operations stood at Rs 2,391.41 crore for the quarter under consideration as against Rs 2,385.58 crore for the same period year ago, it added.
-
May 12, 2020 09:10 PM IST Under the licencing agreement, the company has the right to receive technology transfer of the Gilead manufacturing process to scale up production.
-
Apr 21, 2020 01:14 PM IST In December quarter, he held 3.45 percent stake in the company, which meant the shareholding increased by 0.96 percent during the March quarter.